Atlas Trials

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Clinical trial NCT03735966 · COMPLETED

Trial details

NCT number
NCT03735966
Sponsor
Henan Cancer Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 Positive Breast Cancer
Start date
2018-11-20
Primary completion
2020-10-20
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.